Pharmaceutical Firms

Sun Pharma weighs multiple funding options for $12 billion Organon deal

The Indian drugmaker is considering seeking consent from Organon bondholders to swap their holdings into Sun Pharma debt

Laurus Labs rallies 6%, hits record high post Q4 results; brokerages upbeat

Laurus Labs is now getting the benefit of the same as the CDMO quarterly run rate has gone up from ₹220-250 crore to ₹450-500 crore in two years, believe analysts.

Sun Pharmaceutical acquires US-based Organon in $11.75 billion deal

Combined entity to have revenue of $12.4 billion; enters biosimilars big league

Sun Pharma to acquire US drugmaker Organon in $11.75 billion all-cash deal

April 26 (Reuters) - India's Sun Pharmaceutical Industries ​will uy Organon & ​Co in an all-cash ‌deal, valuing the U.S. drugmaker at about $11.75 billion including ebt, the companies said on Sunday.

Results preview: Pharma growth steady in Q4, but US drag weighs on margins

India's pharma and healthcare firms may post steady Q4 revenue growth, but weak US generics and rising costs are likely to keep margins under pressure

US pharma tariffs: CDMOs with innovator exposure likely to take a hit

Proposed US tariffs on patented drugs may pressure innovators to shift production locally, creating uncertainty for Indian CDMOs even as generics-led exports remain largely insulated

Trump imposes 100% tariff on patented drug imports; generics spared

The US has announced a 100 per cent tariff on patented pharma imports from countries like India without reshoring deals, aiming to boost local production, while generics have been exempted for now

Govt to intensify surveillance, audits against unauthorised GLP-1 sales

Online pharmacies, drug wholesalers under scanner; non-compliance may lead penalties, license cancellations

Acutaas Chemicals zooms 50% in 2 months, hits new high; here's why

In the past one month, the stock price of pharmaceuticals company has gained 15 per cent, as compared to 11 per cent decline in the BSE Sensex.

Uttar Pradesh to get major pharma boost with ₹2,500 crore investment

Uttar Pradesh is ramping up investments in pharma parks and medical device manufacturing to emerge as a major healthcare production hub in South Asia

Companies eye alternatives after CDSCO bans weight-loss drug ads

Firms may shift to doctor outreach, CME programmes and patient support initiatives as CDSCO bars advertising of GLP-1 drugs ahead of semaglutide patent expiry

Natco rallies 5%, nears 52-week high; what's driving pharma stock?

In the past four trading days, the stock price of Natco Pharma has surged 10 per cent after the company announced the launch of Pomalidomide Capsules (generic of Pomalyst) in the US market.

Emcure Pharmaceuticals soars 9% in weak market on huge volumes

Emcure Pharmaceuticals stock was quoting close to its 52-week high of ₹1,585.50 on Monday, and has surged up to 62% in the last one year.

Indian pharma market grows 11% in Feb as Mounjaro tops drug sales

The Indian pharmaceutical market posted 11% growth in February 2026, driven by strong therapy performance, while Mounjaro remained India's highest-selling drug by value for a fifth month

Indian CDMOs expand capacity as demand for complex drug work rises

Indian CDMOs are expanding manufacturing capacity and investing in advanced technologies as global pharma companies increasingly outsource complex drug development and manufacturing work

Sai Life hits record high in weak market; rebounds 5% from day's low

Supported by solid demand, disciplined execution, and capex programs progressing as planned, Sai Life management remains confident in sustaining positive growth momentum.

Drugmakers may review shipment schedules to West Asia if conflict drags on

Indian drugmakers are reviewing shipment schedules and inventories for West Asia as escalating tensions threaten sea and air routes, raising freight costs and risking supply delays

Cipla, Kemwell form biologics JV to tap fast-growing biosimilars market

Cipla will hold 60% in the new JV with Kemwell Biopharma, aiming to develop, manufacture and commercialise biologics and biosimilars for global markets amid rising demand

Sai Life soars 25% in 5 weeks, hits record high in weak market; here's why

ICRA expects Sai Life Sciences to maintain strong growth momentum over the medium term on the back of a healthy growth outlook for the industry, good product mix and deepening customer engagement.

CDSCO modifies norms for testing permissions to speed up drug approvals

In a move aimed at speeding up approvals for new drugs, the government has changed the way testing permissions are granted, allowing companies to begin laboratory testing immediately after filing applications instead of waiting for detailed scrutiny. In an official circular, the country's apex drug regulatory authority, Central Drugs Standard Control Organization (CDSCO), said it has decided that "No Objection Certificate (NOC) for testing of drug samples at the designated laboratories (IPC, Ghaziabad; CDTL, Mumbai; CDL at CRI, Kasauli; or NIB, Noida) shall be issued immediately upon receipt of applications in the concerned division." Earlier, the regulator examined detailed specifications submitted by applicants before issuing permission for testing. These included "Type of formulation, dosage form, Critical Quality Attributes (CQAs), and general characteristics of the product," along with "Product development reports, forced degradation studies, and other relevant data, in ...